Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Biochim Biophys Acta. 2012 Apr 3;1826(1):199–208. doi: 10.1016/j.bbcan.2012.03.012

Figure 1. Prevalence of serum HER2 ECD in breast cancer.

Figure 1

This a summary of 70 studies published between 1991–2011 (see Table S1 for detail). In average, abnormal levels of HER2 ECD were found in 33% of all breast cancers (Total BC), 18% of primary breast cancer (PBC), 23% of breast cancers with locoregional recurrence (loco Recur), and 44% of metastatic breast cancer (MBC).